Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

malignant pleural mesothelioma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

malignant pleural mesothelioma

MONDO:0005112

Also known as:pleura mesotheliomamalignant mesothelioma of pleuramalignant mesothelioma of the pleura

Find Clinical TrialsTrials

Overview

A malignant neoplasm that arises from mesothelial cells in the pleura and shows a diffuse growth pattern. It arises on the parietal and sometimes visceral pleura as multiple small nodules that later become confluent and invade the chest wall adipose tissue and muscle. Asbestos exposure is the main cause for the development of pleural malignant mesothelioma. It usually affects patients over sixty years of age. The latency period is long. Patients usually present with pleural effusion, dyspnea and chest wall pain. Additional signs and symptoms include chills, sweating, weight loss, and weakness. Morphologic variants include epithelioid, desmoplastic, sarcomatoid, and biphasic mesothelioma. The clinical course is usually aggressive.

Treatments3 FDA approved

Clinical Trials52 registered · 25 recruiting

Diagnosis

Biomarker and diagnostic research for malignant pleural mesothelioma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for malignant pleural mesothelioma, including PEMETREXED DISODIUM (ALIMTA, approved 2004). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

52 clinical trials registered, 25 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE3, 14 PHASE2, 21 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT04400539](https://clinicaltrials.gov/study/NCT04400539)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of ALIMTA for managing malignant pleural mesothelioma?
→Are any of the 52 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	9	32%
Laboratory research	5	18%
Disease patterns and progression	4	14%
Patient case studies	3	11%
Other research	2	7%
Testing and diagnosis research	2	7%
New treatment approaches	2	7%
Clinical study results	1	4%

Kisho

malignant pleural mesothelioma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

First report of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan: a case report.

Delayed Solitary Adrenal Metastasis in Malignant Pleural Mesothelioma with Long-Term Survival under Immunotherapy.

malignant pleural mesothelioma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

First report of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan: a case report.

Delayed Solitary Adrenal Metastasis in Malignant Pleural Mesothelioma with Long-Term Survival under Immunotherapy.